DOCSLIB.ORG

DPP-4 Inhibitors and Heart Failure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DPP-4 Inhibitors and Heart Failure CARDIOVASCULAR DISEASE AND DIABETES Diabetes Care Volume 39, May 2016 735 DPP-4 Inhibitors and Heart Kristian B. Filion and Samy Suissa Failure: Some Reassurance, Some Uncertainty Diabetes Care 2016;39:735–737 | DOI: 10.2337/dci15-0036 The American Diabetes Association’s or placebo (5) (Table 1). Patients ran- data across all three cardiovascular out- Standards of Medical Care in Diabetesd domly assigned to saxagliptin unexpect- come trials results in an HR of 1.15 (95% 2016 recommends the use of dipeptidyl edly had a significantly higher risk of CI 0.98–1.34) (Fig. 1). peptidase 4 (DPP-4) inhibitors in combina- hospitalization for HF (hazard ratio [HR] The safety signal raised by the SAVOR- tion with metformin as a second- or third- 1.27 [95% CI 1.07–1.51]), a prespecified TIMI 53 trial has led to several observa- line treatment for type 2 diabetes (1). component of the secondary composite tional studies that produced somewhat Owing to their relatively high costs, end point. This increased risk was clus- conflicting results (10–17). In this issue many jurisdictions restrict their use to tered in the first year of follow-up (HR of Diabetes Care, Fu et al. (18) report the patients whose glycemia remains poorly 1.46 [95% CI 1.15–1.88]) with no increase results of a retrospective cohort study controlled on metformin–sulfonylurea thereafter (6). that compared the risk of hospitalization combination therapy. By inhibiting DPP-4 The increased HF risk in SAVOR-TIMI for HF with DPP-4 inhibitors to that of activity, these agents increase postpran- 53 was not observed in subsequent tri- sulfonylureas and, in secondary analy- dial incretin concentrations, thereby in- als (Table 1). In the Examination of Car- ses, directly compared the HF risks of creasing insulin secretion and decreasing diovascular Outcomes with Alogliptin saxagliptin and sitagliptin. Exposure glucagon secretion (1). With intermediate versus Standard of Care (EXAMINE) trial, was defined using an as-treated ap- efficacy, a low risk of hypoglycemia, neu- 5,380 patients with type 2 diabetes proach, in which patients were censored tral effects on body weight, and relatively and a recent hospitalization for acute upon discontinuation of their cohort en- rare adverse effects (1), their use has in- coronary syndrome were randomly as- try therapy or switching to the other creased considerably since their 2006 en- signed to alogliptin (Nesina in the U.S. drug. Using propensity score matching, try into the U.S. market (2). Nevertheless, and Vipidia in Europe) or placebo (7). the authors found no evidence of an in- concerns remain regarding their potential Overall, alogliptin was not associated creased risk of hospitalization for HF with association with serious adverse effects with an increased risk of hospitalization DPP-4 inhibitors among patients with including acute pancreatitis (3), pancre- for HF (HR 1.19 [95% CI 0.90–1.58]), but CVD history at baseline (HR 0.95 [95% CI atic cancer (3), and heart failure (HF) (4). the risk differed among patients with 0.78–1.15]) and with no CVD history (HR The potential increased risk of HF (HR 1.00 [95% CI 0.71–1.42]) and with- 0.59 [95% CI 0.38–0.89]). Similarly, no dif- with DPP-4 inhibitors was reported in out (HR 1.76 [95% CI 1.07–2.90]) a his- ference was observed when comparing the Saxagliptin Assessment of Vascular tory of HF (P for interaction = 0.068) (8). saxagliptin to sitagliptin (HR 0.95 [95% Outcomes Recorded in Patients with Most recently, the Trial Evaluating Car- CI 0.70–1.28] and HR 0.99 [95% CI 0.56– Diabetes Mellitus–Thrombolysis in Myo- diovascular Outcomes with Sitagliptin 1.75], respectively). cardial Infarction 53 (SAVOR-TIMI 53) (TECOS) randomized 14,671 patients to The study by Fu et al. (18) has several trial, which randomized 16,492 patients sitagliptin (Januvia) or placebo and ob- strengths. These include a large sample with type 2 diabetes and either a history served no difference in the risk of size of 218,556 patients and the use of of cardiovascular disease (CVD) or multiple hospitalization for HF (adjusted HR propensity scores to minimize confound- CVD risk factors to saxagliptin (Onglyza) 1.00 [95% CI 0.83–1.20]) (9). Pooling ing. Furthermore, the head-to-head Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada; Division of Clinical Epidemiology, Department of Medicine, McGill University, Montreal, Quebec, Canada; and Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada Corresponding author: Samy Suissa, [email protected]. ©2016 by the American Diabetes Association.Readersmay use this article as long as thework is properly cited, the useis educational and not for profit, and the work is not altered. See accompanying articles, pp. 664, 668, 677, 686, 694, 701, 709, 717, 726, and 738. 736 Commentary Diabetes Care Volume 39, May 2016 Table 1—Data from randomized placebo-controlled trials of DPP-4 inhibitors and the risk of HF Hospitalization for HF Rate (no. per 100 PYs) Sample Median follow-up Study Year DPP-4 inhibitor Population size (years) DPP-4 inhibitor Placebo HR (95% CI) SAVOR-TIMI 2013, 2014 Saxagliptin CVD or multiple 16,492 2.1 1.71* 1.36* 1.27 (1.07–1.51) 53 (5,6) CVD risk factors EXAMINE (7,8) 2013, 2015 Alogliptin Post-ACS 5,380 1.5 2.69† 2.28† 1.19 (0.90–1.58) With history of HF 1,533 5.60† 5.85† 1.00 (0.71–1.42) With no history of HF 3,847 1.53† 0.86† 1.76 (1.07–2.90) TECOS (9) 2015 Sitagliptin CVD 14,671 3.0 1.07 1.09 1.00 (0.83–1.20)‡ ACS, acute coronary syndrome; PYs, person-years. *Estimated using the total person-years of follow-up reported for each group (16,884 for saxagliptin and 16,761 for placebo). †Estimated using the median duration of follow-up for the trial. ‡Adjusted for baseline history of HF. comparison of saxagliptin and sitagliptin light on this potential issue. In addition, There are several potential explana- represents an important addition to the despite matching on propensity score, tions for the discordance in data from literature particularly in light of the con- the potential for confounding remains, trials and observational studies regard- flicting trial evidence on this issue. In ad- particularly from formulary restrictions ing DPP-4 inhibitors and the risk of HF. dition, given the inherent differences with DPP-4 inhibitors in place in many First, it is possible that the safety signal between patients who participate in jurisdictions, which can result in impor- observed in SAVOR-TIMI 53 (5,6) and clinical trials and those seen in everyday tant bias in pharmacoepidemiologic re- in the post hoc subgroup analyses of clinical practice (19,20), these data search (21). Finally, although the study EXAMINE (8) are chance findings due should provide some reassurance to restricted the cohort to new users of to multiple testing. Second, it is possible practicing clinicians and patients with the study drugs, the recommended ap- that the increased risk of HF is specificto type 2 diabetes. proach to avoid bias from the inclusion of saxagliptin, the DPP-4 inhibitor examined This study also has important limita- prevalent users (22), the exclusion of in SAVOR-TIMI 53. Although Fu et al. com- tions, many of which are acknowledged patients who previously used sulfonyl- pared the HF risks of saxagliptin and sita- by the authors. With a mean follow-up ureas can be highly restrictive, even gliptin, with a mean follow-up of 6 months, of only 6 months (median 3 months), the more so than many randomized trials. theiranalysis in patients with a history of duration of follow-up may have been in- This is a potential major limitation of CVD (the population studied in SAVOR- adequate to fully assess the HF risk of this approach; its scope can be far re- TIMI 53) was underpowered, as they DPP-4 inhibitors. Concerns regarding this moved from the real-world data expected only ruled out HRs above 1.75 (18). Fi- limitation are partially mitigated by the from such studies. Moreover, given the nally, the heterogeneity in comparators earlyriskidentified in SAVOR-TIMI 53 (6), progressive nature of type 2 diabetes and their corresponding HF risks must but it remains important in interpreting and its multistep treatment, the study be considered. All three trials were pla- these data. Informative censoring upon of antidiabetes drugs is a challenging cebo-controlled but encouraged the use discontinuation of study medication must area in pharmacoepidemiology that of nonstudy medications to maintain also be considered; the inclusion of an is particularly ripe for selection and glycemic control; differences in the dis- analysis analogous to an intention-to- time-related biases (23). Despite these tribution of use of these drugs (and treat approach where exposure is de- limitations, this study (18) joins several their HF risks) may explain some het- fined at cohort entry and patients are observational studies that have found no erogeneity in risk estimates. On the followed for a fixed duration of follow- evidence of an increased HF risk with other hand, many of the observational up (e.g., 6 or 12 months) could shed DPP-4 inhibitors (13–17). studies used sulfonylureas as the comparator, a drug class that has been associated with increased cardiovascu- lar risk (24). The observational study by Fu et al. (18) provides some welcome reassurance re- garding the HF risk of DPP-4 inhibitors.
Load more

Recommended publications
  • Treatment of Diabetes Mellitus
    TREATMENT OF DIABETES MELLITUS DIABETES is a condition that affects how the body makes energy from food. Food is broken down into sugar (glucose) in the body and released into the blood. When the blood sugar level rises after a meal, insulin responds to let the sugar into the cells to be used as energy. In diabetes, the body either does not make enough insulin or it stops responding to insulin as well as it should. This results in sugar staying in the blood and leads to serious health problems over time. DIAGNOSIS OF DIABETES1 • A1C Test: Lab test measuring average blood sugar over past two to three months • Fasting Blood Sugar Test: Lab test measuring blood sugar after eight hours of no food or drink • Oral Glucose Tolerance Test (OGTT): Measures blood sugar before and two hours after drinking a specific sugary liquid • Random Blood Sugar Test: Measures blood sugar at a moment in time, without any kind of preparation (like fasting) FASTING BLOOD ORAL GLUCOSE TOLERANCE RANDOM BLOOD RESULT A1C TEST SUGAR TEST TEST SUGAR TEST Diabetes ≥ 6.5% ≥126 mg/dL ≥ 200 mg/dL ≥ 200 mg/dL Prediabetes 5.7 – 6.4% 100 – 125 mg/dL 140 – 199 mg/dL N/A Normal < 5.7% ≤99 mg/dL < 140 mg/dL N/A NON-DRUG TREATMENTS2 THERAPY COST WHAT TO EXPECT Diet (Mediterranean diet) and exercise (30 minutes a day, five days a week of moderate- Weight loss $-$$ intensity exercise); 7% weight loss decreases risk of diabetes3 Psychological intervention $$-$$$ Psychotherapy may reduce diabetic distress and improve glycemic control4,5 nationalcooperativerx.com PRESCRIPTION TREATMENTS
    [Show full text]
  • Januvia (Sitagliptin) Tablets
    CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: NDA 021995/S-013 Trade Name: JANUVIA Generic Name: Sitagliptin Sponsor: Merck & Co., Inc. Approval Date: 12/28/2009 Indications: JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: NDA 021995/S-013 CONTENTS Reviews / Information Included in this NDA Review. Approval Letter X Other Action Letters X Labeling X Summary Review Officer/Employee List Office Director Memo Cross Discipline Team Leader Review Medical Review(s) X Chemistry Review(s) Environmental Assessment Pharmacology Review(s) X Statistical Review(s) Microbiology Review(s) Clinical Pharmacology/Biopharmaceutics Review(s) Risk Assessment and Risk Mitigation Review(s) X Proprietary Name Review(s) Other Review(s) X Administrative/Correspondence Document(s) X CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: NDA 021995/S-013 APPROVAL LETTER DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021995/S-013 SUPPLEMENT APPROVAL Merck & Co., Inc. Attention: Richard J. Swanson, Ph.D. Director, Regulatory Affairs P.O. Box 1000, UG2C-50 North Wales, PA 19454-1099 Dear Dr. Swanson: Please refer to your supplemental new drug application (S-013) dated and received March 5, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Januvia (sitagliptin) tablets. We also refer to your supplemental new drug application (b) (4) dated and received November 13, 2009. Your submission of November 13, 2009, also constitutes a complete response to our October 16, 2009, action letter for supplemental application S-013.
    [Show full text]
  • Onglyza (Saxagliptin) Uses, Dosage, Side Effects - Drugs.Com 04/07/2015 Insulin Pump – Tubeless Feel the Freedom for Yourself! Learn About the Omnipod®
    Onglyza (saxagliptin) Uses, Dosage, Side Effects - Drugs.com 04/07/2015 Insulin Pump – Tubeless Feel The Freedom For Yourself! Learn About The OmniPod®. Browse all medications A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Advanced Search Phonetic Search Drugs A-Z Pill Identifier Interactions Checker News Health Professionals Q & A Mednotes Apps Home → Conditions → Diabetes, Type 2 → Onglyza Print Share Sign In or Register Onglyza Related Information Availability Pregnancy Category Generic Name: saxagliptin (SAX a GLIP tin) Prescription only No proven risk in Brand Names: Onglyza humans CSA Schedule Not a controlled drug Approval History Drug history at FDA Overview Side Effects Dosage Interactions For Professionals More Reviews Average User Rating Insulin Pump – Tubeless Feel The Freedom For Yourself! Learn About The 9 User Reviews 7.6 Rate it! OmniPod® Drug Class What is Onglyza? Dipeptidyl peptidase 4 inhibitors Onglyza (saxagliptin) is an oral diabetes medicine that helps control blood sugar levels . It works by regulating Related Drugs the levels of insulin your body produces after Diabetes, Type 2 eating. metformin Onglyza is for people with type 2 diabetes. It is insulin aspart Januvia sometimes used in combination with other glipizide diabetes medications, but is not for treating glimepiride type 1 diabetes . Lantus Onglyza may also be used for purposes not Invokana listed in this medication guide. Victoza glyburide Levemir Humalog Actos Important information Janumet You should not use Onglyza if you are in a state of diabetic ketoacidosis (call your doctor for Glucophage treatment with insulin).
    [Show full text]
  • Komboglyze, INN-Saxagliptin, Metformin
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Komboglyze 2.5 mg/850 mg film-coated tablets Komboglyze 2.5 mg/1,000 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Komboglyze 2.5 mg/850 mg film-coated tablets Each tablet contains 2.5 mg of saxagliptin (as hydrochloride) and 850 mg of metformin hydrochloride. Komboglyze 2.5 mg/1,000 mg film-coated tablets Each tablet contains 2.5 mg of saxagliptin (as hydrochloride) and 1,000 mg of metformin hydrochloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Komboglyze 2.5 mg/850 mg film-coated tablets Light brown to brown, biconvex, round, film-coated tablets, with “2.5/850” printed on one side and “4246” printed on the other side, in blue ink. Komboglyze 2.5 mg/1,000 mg film-coated tablets Pale yellow to light yellow, biconvex, oval shaped, film-coated tablets, with “2.5/1000” printed on one side and “4247” printed on the other side, in blue ink. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Komboglyze is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products (see sections 4.4, 4.5 and 5.1 for available data on different combinations) in patients already being treated with the combination of saxagliptin and metformin as separate tablets.
    [Show full text]
  • Pharmacokinetics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 Inhibitor
    Available online a t www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2016, 8(12):292-295 CODEN (USA): PCHHAX (http://derpharmachemica.com/archive.html) Mini-review: Pharmacokinetics of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor Nermeen Ashoush a,b aClinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, British University in Egypt, El- Sherouk city, Cairo 11837, Egypt. bHead of Health Economics Unit, Center for Drug Research and Development (CDRD), Faculty of Pharmacy, British University in Egypt, El-Sherouk city, Cairo 11837, Egypt. _____________________________________________________________________________________________ ABSTRACT The dipeptidyl peptidase-4 (DPP-4) inhibitors are novel oral hypoglycemic drugs which have been in clinical use for the past 10 years. The drugs are safe, weight neutral and widely prescribed. There are currently many gliptins approved by FDA, namely sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin with several more in advanced stages of development. The gliptins may possess cardiovascular protective effects and their administration may promote β-cell survival; claims currently being evaluated in clinical and preclinical studies. The gliptins are an optional second-line therapy after metformin; they are generally well tolerated with low risk of hypoglycemia. The various compounds differ with respect to their pharmacokinetic properties; however, their clinical efficacy appears to be similar. The clinical differences between the various compounds
    [Show full text]
  • TREATMENT of TYPE 2 DIABETES with BIPHASIC INSULIN ANALOGUES *Ali A
    TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES *Ali A. Rizvi Professor of Medicine, Department of Medicine and Director, Division of Endocrinology, University of South Carolina School of Medicine, Columbia, South Carolina, USA *Correspondence to [email protected] Disclosure: The author has received grant support, as principal investigator at the University of South Carolina site, from the National Institutes of Health (NIH) for the SPRINT Trial (Contract Number: HHSN268200900040C, ClinicalTrials.gov Identifier: NCT01206062). The contents of this paper do not necessarily represent the views of the NIH. Received: 29.03.16 Accepted: 09.09.16 Citation: EMJ Diabet. 2016;4[1]:74-83. ABSTRACT The majority of patients with Type 2 diabetes require insulin therapy for treating hyperglycaemia. There are several regimens available for insulin initiation and maintenance. Insulin analogues have been developed to mimic normal physiology as closely as possible. Biphasic analogues can target both fasting and postprandial hyperglycaemia, with the added advantage of being premixed and thus convenient for the patient. A practical and feasible option is to initiate insulin with one or more biphasic preparations at mealtimes, thus providing both basal and prandial coverage. Individual titration of dose and frequency of daily injections with biphasic insulin preparations has the potential for improving glycaemic control with a high degree of patient acceptance. Drawbacks include a more rigid regimen, a relative lack of flexibility, and a somewhat higher degree of glycaemic variability and hypoglycaemia when compared to multiple daily basal-bolus injections. Awareness of the advantages and limitations of biphasic insulin analogues can assist clinicians in their appropriate use for the treatment of patients with Type 2 diabetes.
    [Show full text]
  • Sitagliptin: a New Class of Oral Drug for Type 2 Diabetes
    JK SCIENCE DRUG REVIEW Sitagliptin: a New Class of Oral Drug for Type 2 Diabetes Dinesh K. Badyal, Jasleen Kaur Introduction Pharmacokinetics Type 2 diabetes is the most common form of the Bioavailability of sitagliptin is approximately 87%. Half- disease, accounting for about 90% to 95 % of all diagnosed life is between 8-14 hours. It is 38% bound to plasma cases of diabetes. In type 2 diabetes, the body does not proteins. It undergoes limited metabolism via CYP3A4 produce enough insulin or the cells ignore the insulin. and CYP2C8. Elimination is mainly through urine (5, 6). Over time, high blood sugar levels can increase the risk Clinical Use for serious complications, including heart disease, In October 2006, the U.S. Food and Drug blindness, nerve damage and kidney damage (1). Any Administration (FDA) approved sitagliptin as new oral hypoglycemic drug that can increase the control monotherapy and as add-on therapy to either of two other of blood glucose with fewer adverse effects in patients types of oral diabetes medications, metformin or with diabetes may be welcomed. Sitagliptin is the first thiazolidinediones to improve blood glucose control in and only prescription medication in a new class of oral patients with type 2 diabetes when diet and exercise are antihyperglycemic agents, which enhance the body's own not enough (5). In March, 2007 it was approved in ability to lower blood glucose when it is elevated (2). European Union. Sitagliptin is currently approved in 42 Mechanism of Action countries (7). The recommended dose of sitagliptin is Sitagliptin prolongs the activity of proteins that increase 100 mg once daily.
    [Show full text]
  • Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly
    2106 Diabetes Care Volume 38, November 2015 fi Wayne H.-H. Sheu,1 Ira Gantz,2 Safety and Ef cacy of Omarigliptin Menghui Chen,2 Shailaja Suryawanshi,2 Arpana Mirza,2 Barry J. Goldstein,2 (MK-3102), a Novel Once-Weekly Keith D. Kaufman,2 and Samuel S. Engel2 DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes Diabetes Care 2015;38:2106–2114 | DOI: 10.2337/dc15-0109 OBJECTIVE This study was conducted to determine the optimal dose of omarigliptin, a once- weekly (q.w.) dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of patients with type 2 diabetes and evaluate the long-term safety of that dose. RESEARCH DESIGN AND METHODS In a multicenter, double-blind, 12-week, dose-range finding study, 685 oral antihy- perglycemic agent-na¨ıve or washed-out subjects with type 2 diabetes were random- ized to one of five once-weekly doses of omarigliptin (0.25 mg, 1 mg, 3 mg, 10 mg, or 25 mg) or placebo. The primary efficacy end point was change from baseline in HbA1c, and secondary end points were 2-h postmeal glucose (PMG) and fasting plasma glucose (FPG). Analysis included all patients who received at least one dose of the study medication. Subjects who completed the base study were eligible to enter a 66-week extension study. RESULTS Once-weekly treatment for 12 weeks with omarigliptin provided dose-related reduc- 1Division of Endocrinology and Metabolism, De- partment of Internal Medicine, Taichung Veterans EMERGING TECHNOLOGIES AND THERAPEUTICS tions in HbA , 2-h PMG, and FPG.
    [Show full text]
  • Reference ID: 3912436 FULL PRESCRIBING INFORMATION
    HIGHLIGHTS OF PRESCRIBING INFORMATION Hypoglycemia: In add-on to sulfonylurea, add-on to insulin, and add-on These highlights do not include all the information needed to use to metformin plus sulfonylurea trials, confirmed hypoglycemia was ONGLYZA safely and effectively. See full prescribing information for more common in patients treated with ONGLYZA compared to placebo. ONGLYZA. When used with an insulin secretagogue (e.g., sulfonylurea) or insulin, a lower dose of insulin secretagogue or insulin may be required to ONGLYZA (saxagliptin) tablets, for oral use minimize the risk of hypoglycemia. (5.3, 6.1) Initial U.S. Approval: 2009 Hypersensitivity-Related Events (e.g., urticaria, facial edema): More common in patients treated with ONGLYZA than in patients treated -------------------------- RECENT MAJOR CHANGES -------------------------- with placebo; and postmarketing reports of serious hypersensitivity Warnings and Precautions reactions such as anaphylaxis, angioedema, and exfoliative skin Pancreatitis (5.1) 4/2016 conditions. Promptly discontinue ONGLYZA, assess for other potential Heart Failure (5.2) 4/2016 causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. (5.4, 6.1, 6.2) --------------------------- INDICATIONS AND USAGE -------------------------- Arthralgia: Severe and disabling arthralgia has been reported in patients ONGLYZA is a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an taking DPP4 inhibitors. Consider as a possible cause for severe joint adjunct to diet and exercise to improve glycemic control in adults with type 2 pain and discontinue drug if appropriate. (5.5) diabetes mellitus. (1.1, 14) Macrovascular Outcomes: There have been no clinical studies Limitation of use: establishing conclusive evidence of macrovascular risk reduction with Not used for the treatment of type 1 diabetes mellitus or diabetic ONGLYZA or any other antidiabetic drug.
    [Show full text]
  • Januvia (Sitagliptin)
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 3084-7 Program Step Therapy – Diabetes Medications- DPP4 Inhibitors Medication Januvia (sitagliptin)*, Janumet (sitagliptin/metformin immediate- release)*, Janumet XR (sitagliptin/metformin extended-release)* P&T Approval Date 10/2016, 10/2017, 1/2018, 10/2019, 4/2020, 5/2020, 5/2021 Effective Date 8/1/2021; Oxford only: 8/1/2021 1. Background: Januvia (sitagliptin)* is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Janumet (sitagliptin/metformin)* and Janumet XR (sitagliptin/metformin extended-release)* are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin/metformin extended-release is appropriate. 2. Coverage Criteriaa: A. Januvia* will be approved based on the following criterion: 1. History of a three month trial resulting in a therapeutic failure, contraindication (e.g. risk factors for heart failure), or intolerance to both of the following (list reason for therapeutic failure, contraindication, or intolerance)b: a. Tradjenta (linagliptin) -AND- b. One of the following: (1) Nesina (alogliptin) (2) Onglyza (saxagliptin) Authorization will be issued for 12 months B. Janumet* and Janumet XR* will be approved based on the following criterion: 1. History of a three month trial resulting in a therapeutic failure, contraindication (e.g. risk factors for heart failure), or intolerance to all of the following (list reason for therapeutic failure, contraindication, or intolerance)b: a. Jentadueto (linagliptin/metformin immediate-release)/Jentadueto XR (linagliptin/metformin extended-release) -AND- b.
    [Show full text]
  • KOMBIGLYZE XR Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------WARNINGS AND PRECAUTIONS----------------------- These highlights do not include all the information needed to use Lactic acidosis: Warn patients against excessive alcohol intake. KOMBIGLYZE XR safely and effectively. See full prescribing KOMBIGLYZE XR not recommended in hepatic impairment and information for KOMBIGLYZE XR. contraindicated in renal impairment. Ensure normal renal function KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) before initiating and at least annually thereafter. Temporarily tablets discontinue KOMBIGLYZE XR in patients undergoing radiologic Initial U.S. Approval: 2010 studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and WARNING: LACTIC ACIDOSIS fluids. (4, 5.1, 5.3, 5.4, 5.7, 5.10, 5.11) See full prescribing information for complete boxed warning. There have been postmarketing reports of acute pancreatitis in patients Lactic acidosis can occur due to metformin accumulation. The taking saxagliptin. If pancreatitis is suspected, promptly discontinue risk increases with conditions such as sepsis, dehydration, excess KOMBIGLYZE XR. (5.2) alcohol intake, hepatic impairment, renal impairment, and acute Vitamin B12 deficiency: Metformin may lower vitamin B12 levels. congestive heart failure. (5.1) Measure hematological parameters annually. (5.5, 6.1) Symptoms include malaise, myalgias, respiratory distress, Hypoglycemia: When used with an insulin
    [Show full text]
  • Combination Use of Insulin and Incretins in Type 2 Diabetes
    Canadian Agency for Agence canadienne Drugs and Technologies des médicaments et des in Health technologies de la santé CADTH Optimal Use Report Volume 3, Issue 1C Combination Use of Insulin and July 2013 Incretins in Type 2 Diabetes Supporting Informed Decisions This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). The report contains a comprehensive review of the existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time of report preparation. The information in this report is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this document to ensure that its contents are accurate, complete, and up to date as of the date of publication, CADTH does not make any guarantee to that effect. CADTH is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in the source documentation. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the information in this document or in any of the source documentation.
    [Show full text]